## PRODUCT TRANSFER AGREEMENT

#### BETWEEN

## The CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,

A national public scientific and technological establishment,

SIREN no. 180 089 013 - APE code 7219Z,

Having its registered office at 3 rue Michel Ange, 75794 Paris Cedex 16,

Represented by its CEO, M. Antoine Petit, who has delegated signing authority for this agreement to M. Jérôme VITRE, the CNRS' Regional Delegate for the Occitanie Est region.

Hereinafter referred to as the "CNRS",

Acting both in its own name and on behalf of the UAR no. 3035 "*Unité support de ChemBioFrance et de la Chimiothèque Nationale*" (Management Unit of ChemBio France and the National Chemical Library), managed by M. Jean-Luc GALZI,

Hereinafter referred to as the "USCBF-CN",

And

- XXXXXX Organisation [to be completed for each supervisory organisation°]

Hereinafter referred to as " .....",

And

- XXXXXX Organisation [to be completed for each supervisory organisation°]

Hereinafter referred to as " .....",

And

- XXXXXX Organisation [to be completed for each supervisory organisation°]

Hereinafter referred to as " .....",

The CNRS and the XXX supervisory organisation(s), acting both in their own name and in the name and on behalf of the relevant unit or units or team(s), identified as laboratory(ies) participating in the *Groupement d'Intérêt Scientifique " ChemBio France"* (hereinafter the "GIS CBF") and listed in Appendix I, (hereinafter the "Laboratories"), are hereinafter referred to jointly as the "**Relevant Parties of the GIS CBF**".

It is hereby stipulated that, pursuant to this Agreement, the Relevant Parties of the GIS CBF only commit themselves to the obligations binding upon the Laboratories which are attached to them and for the part concerning the PRODUCTS which they own.

## PARTIES OF THE FIRST PART

## AND

## Company or Organisation

A French Joint Stock Company (SA) with capital of registered with the \_\_\_\_\_ Trade and Companies Registry intra-Community VAT no. having its registered office at represented by

Hereinafter referred to as the "Beneficiary",

## PARTIE OF THE SECOND PART

The Relevant Parties of the GIS CBF and the Beneficiary are hereinafter individually referred to as a "Party" and jointly as the "Parties".

## WHEREAS:

Within the context of the GIS CBF, the Relevant Parties of the GIS CBF have established an archived and formatted collection of natural substances, synthetic substances and natural extracts, referenced in a common database accessible via the website managed by the USCBF-CN.

Pursuant to carrying-out its research work, the Beneficiary is interested in receiving a certain number and a certain volume of PRODUCTS which it has selected by consulting the common database managed by the USCBF-CN.

In these circumstances, the Parties have decided to execute this product transfer agreement (hereinafter the "Agreement").

The provisions of this Agreement shall be written subject to the provisions of the Convention on Biological Diversity (CBD), adopted in Rio de Janeiro on May 22<sup>nd</sup>, 1992 and entered into force on December 29<sup>th</sup>, 1993, especially concerning the fair sharing of the benefits drawn from the exploitation of genetic resources with the provider country (Article 15 of the CBD). And subject to the provisions of the Nagoya Protocol on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of their Utilization, adopted on October 29, 2010 in Nagoya and entering into force on October 12, 2014, to the Convention on Biological Diversity.

## THE FOLLOWING HAS BEEN AGREED UPON:

## **PRELIMINARY ARTICLE - DEFINITIONS**

**SIGNATURE DATE** means the last signature date of this Agreement by all the Parties.

**INFORMATION** means any and all information or data concerning the PRODUCTS and, in particular, the know-how required for the implementation of the PRODUCTS, whether in written, graphic or oral form, regardless of the medium used, which is disclosed pursuant to this Agreement.

**CONFIDENTIAL INFORMATION** means all the INFORMATION bearing the word "confidential". When the INFORMATION is provided orally, its confidential nature shall be stated when it is disclosed and the disclosed INFORMATION shall be stated as such and shall be described or summarised in writing within thirty (30) days of its disclosure.

**PRODUCTS** mean the chemical substances, the preparations containing them and the natural extracts listed and described in Appendix I.

WORK SCHEDULE means the work schedule described in Appendix II.

**RESULTS** mean any and all result of in-house research or tests conducted by the Beneficiary on the PRODUCTS and, in particular, the products created and developed by the Beneficiary from the PRODUCTS or from elements which contain or incorporate all or part of the PRODUCTS, or which use the INFORMATION.

Words in the plural may be understood in the singular form and vice-versa.

## **ARTICLE 1 – PURPOSE AND SCOPE OF THE AGREEMENT**

1.1 Under the Agreement, the Relevant Parties of the GIS CBF undertake to provide the PRODUCTS and the INFORMATION non-exclusively to the Beneficiary and authorise the latter to use said PRODUCTS and INFORMATION during the term provided for in Article 2, solely for its in-house research work or tests and pursuant to the WORK SCHEDULE, to the exclusion of any and all other work, in particular, commercial activity, even free-of-charge. Such furnishing is personal and non-assignable.

The Beneficiary accepts that the PRODUCTS and INFORMATION be provided by the Relevant Parties of the GIS CBF pursuant to this Agreement for research on laboratory animals and/or in vitro studies, and that said PRODUCTS and INFORMATION may under no circumstances be used on human beings.

1.2 The Beneficiary undertakes not to transfer nor disclose the PRODUCTS or INFORMATION to third Parties.

1.3 In particular, the Beneficiary undertakes not to file applications for patents or other industrial property titles related to the PRODUCTS or incorporating the INFORMATION, without the prior agreement of the Relevant Party(ies) of the GIS CBF.

1.4 The Agreement does not make any transfer of ownership of all or part of the PRODUCTS to the Beneficiary. They remain the property of the Relevant Parties of the GIS CBF.

Moreover, the Agreement does not grant or involve any granting of a licence or any assignment of intellectual property rights or know-how to the Beneficiary. In particular, the Agreement does not grant the Beneficiary any right to manufacture, sell, rent or transfer the PRODUCTS to third parties, nor any right and/or lien whatsoever over the use or utilisation of the INFORMATION, in any respect whatsoever.

# OPTION: Development of the PRODUCT by the Beneficiary alone

[1.5 The BENEFICIARY wishes to develop the PRODUCTS alone and obtain full ownership of the RESULTS. To do so, he pays a lump sum in full discharge.]

# ARTICLE 2 – TERM

The Agreement takes effect on the SIGNATURE DATE for a one (1) year term.

Orders for other PRODUCTS which are placed following the signing of the Agreement shall be materialised by the execution of a new agreement.

At the end of its term, the Agreement may be extended by an amendment written and signed by all the Parties, specifying the purpose and term of such extension.

# ARTICLE 3 – FINANCIAL TERMS

A fixed contribution payable by the BENEFICIARY is set out in Appendix III.

## IF OPTION

[In return for full ownership of the RESULTS for the Beneficiary, a repayment agreement will be drawn up between the CNRS and the Beneficiary. The Beneficiary undertakes to pay the CNRS, on behalf of the Relevant Parties of the GIS CBF, a lump-sum payment in full discharge of its obligations, the amount of which is set out in Appendix III.]

The Beneficiary shall make an order form to M. XXX, *Agent Comptable Secondaire de la Délégation Occitanie Est du CNRS* France.

The invoice shall be established following the order form and the amount of XXX euros (XXX€) shall be done within forty-five days (45) to account no. 10071 34000 00001003417 34, open in the name of the *Agent Comptable Secondaire de la Délégation Occitanie Est du CNRS* France.

## IF NO OPTION

[The expenses relating to returning or destroying the PRODUCTS and furnishing the RESULTS to the Relevant Parties of the GIS CBF, under Articles 5.1 and 8.2 of the Agreement, shall be fully paid by the Beneficiary, which accepts such.]

## **ARTICLE 4 – SCIENTIFIC MANAGERS**

*Name of scientific manager* is the scientific manager for the Beneficiary.

# FOR THE FOLLOWING ARTICLE, CHOOSE ARTICLE 5 ACCORDING TO PRODUCT DEVELOPMENT: IN COLLABORATION (NO OPTION) OR BY THE BENEFICIARY ALONE (OPTION).

## ARTICLE 5 - RESULTS - NO OPTION

5.0 The Parties agree that any use of the results will be in compliance with the Convention on Biological Diversity, adopted in Rio de Janeiro on May 22<sup>nd</sup>, 1992 and entered into force on December 29<sup>th</sup>, 1993. And subject to the provisions of the Nagoya Protocol on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of their Utilization, adopted on October 29, 2010 in Nagoya and entering into force on October 12, 2014, to the Convention on Biological Diversity.

5.1 The Beneficiary undertakes to send the USCBF-CN a written report on all the RESULTS within thirty (30) days of the expiry or termination date of the Agreement. The USCBF-CN shall be responsible for forwarding the RESULTS to the Relevant Parties of the GIS CBF, only for the PRODUCTS which they own.

5.2 The RESULTS obtained following the use of one or more PRODUCTS and/or INFORMATION items belonging to one or more Relevant Parties of the GIS CBF, are the joint property of this or these Relevant Partie(s) of the GIS CBF and the Beneficiary (hereinafter the "Joint Owners").

The other Relevant Parties of the GIS CBF, which are not Joint Owners of said PRODUCTS and/or INFORMATION have no rights over the RESULTS originating from said PRODUCTS.

The Joint Owners of the RESULTS shall discuss in order to organise, within the framework of rules of joint ownership, the terms and conditions governing the joint ownership, prior to any and all commercial and/or industrial use.

5.3 The Joint Owners of the RESULTS are entitled to use them for in-house research purposes.

5.4 Should one of the Joint Owners of the RESULTS wish to commercially or industrially use or utilise them, directly or indirectly, it shall inform the other Joint Owner(s) thereof. It undertakes, subject to the

rights granted to third parties prior to the signing of this Agreement, to negotiate the conditions for such use or utilisation in good faith.

5.5 Should a research programme, intended to optimise one or more hits identified on the PRODUCTS supplied by the Relevant Parties of the GIS CBF, be initiated, the Beneficiary shall inform the Relevant Parties of the GIS CBF thereof in writing and the latter shall then have a preferential right concerning the implementation of such a programme. If the Relevant Parties of the GIS CBF do not exercise their right within three (3) months as from receipt of the written proposal to contract, the Beneficiary shall be entitled to initiate such a programme itself or to entrust said programme to a third party.

5.6 In the event that the RESULTS could be published, the Joint Owners of the RESULTS shall, for the term of the Agreement and for twelve (12) months following its expiry or termination, immediately keep each other informed thereof and undertake, prior to any and all publication, to discuss in order to jointly agree as to the publication strategy to be implemented for the dissemination of the RESULTS. The Joint Owners shall be mentioned in these publications.

Any Joint Owner is authorised to:

•delay publication or communication for a maximum of eighteen (18) months as from the date of the authorisation request if the information contained in the publication or in the communication requires protection by a patent.

•or to change certain specifications, the disclosure of which would be contrary to the provisions of Article 6.

These changes shall not affect the publication's scientific value.

Should a Joint Owner fail to communicate its decision within a maximum of two (2) months as from the publication or communication authorisation request, it shall be deemed to have agreed thereto.

In any and all publication, the Joint Owner Beneficiary undertakes to identify the origin of the PRODUCTS or INFORMATION in the same way as the Relevant Parties of the GIS CBF which are Joint Owners undertake to specify the origin of the RESULTS.

5.7 In the event that the RESULTS could lead to the filing of a patent, the Joint Owners shall immediately keep each other informed thereof and undertake, prior to any and all filing, to discuss in order to jointly agree as to the conditions of protection and use to be implemented in order to protect the RESULTS.

# ARTICLE 5 - RESULTS - OPTION

5.0 The Parties agree that any use of the results will be in compliance with the Convention on Biological Diversity, adopted in Rio de Janeiro on May 22<sup>nd</sup>, 1992 and entered into force on December 29<sup>th</sup>, 1993. And subject to the provisions of the Nagoya Protocol on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of their Utilization, adopted on October 29, 2010 in Nagoya and entering into force on October 12, 2014, to the Convention on Biological Diversity.

5.1 In consideration of the lump-sum payment in full discharge paid by the Beneficiary, the RESULTS obtained from the use of one or more PRODUCTS and/or INFORMATION belong to the Beneficiary. The Relevant Parties of the GIS CBF have no rights on the RESULTS obtained from the said PRODUCTS.

5.2 In the event that the RESULTS are likely to lead to publication, the Beneficiary undertakes to identify the origin of the PRODUCTS or INFORMATION.

5.3 In the event that the RESULTS constitute a technological breakthrough that could not have been achieved without the use of the PRODUCTS, and that would generate unexpected revenues with a significant impact on the Beneficiary's sales, the Beneficiary and the Relevant Parties of the GIS CBF will define the terms and conditions of this additional financial return. If there is no agreement between the Parties, an expert will be appointed.

5.4 It is understood by the Beneficiary that the Relevant Parties of the GIS CBF remain the owners of the PRODUCTS. As such, they retain the right to carry out any research activity, alone or with third parties, on said PRODUCTS. These research activities may lead to the same RESULTS as those obtained by the Beneficiary.

# **ARTICLE 6 – CONFIDENTIALITY**

6.1 Under the Agreement, the Beneficiary undertakes to respect and uphold the strictly confidential nature of the PRODUCTS, the CONFIDENTIAL INFORMATION and the RESULTS.

6.2 The Beneficiary assumes personal responsibility vis-à-vis the Relevant Parties of the GIS CBF for its staff's compliance with the confidential nature of the PRODUCTS, CONFIDENTIAL INFORMATION and RESULTS.

6.3 Under the Agreement, the Relevant Parties of the GIS CBF and the USCBF-CN undertake to respect and uphold the strictly confidential nature of the WORK SCHEDULES and the RESULTS.

6.4 The Relevant Parties of the GIS CBF assume personal responsibility vis-à-vis the Beneficiary for their staff's compliance with the confidential nature of the WORK SCHEDULES and the RESULTS.

6.5 This Article does not apply to CONFIDENTIAL INFORMATION, WORK SCHEDULES and RESULTS for which one of the Parties is able to prove:

- a) that their disclosure was decided on by joint agreement, duly noted in writing, between the Parties, in particular, under the provisions of Article 5.6;
- b) that they belonged to the public domain when they were disclosed or entered the public domain without any negligence by it;
- c) that on the date when they were communicated, it already had them in its possession;
- d) that they were legally received from a third party, without a breach of the Agreement's nondisclosure obligations;
- e) that they were legally disclosed by one of the Parties after having obtained the other Party's prior and written authorisation;
- f) that their disclosure was imposed by the application of a material legal or regulatory provision or by the enforcement of a final legal decision or an arbitration award;
- g) that they were disclosed by the Party from which they originate;
- h) that it can be justified that they were developed by the disclosing Party, independently and in good faith, by its parties of staff who did not have access to the CONFIDENTIAL INFORMATION, WORK SCHEDULES and RESULTS.

The foregoing exceptions are not cumulative.

6.6 The provisions of this Article take effect as from the SIGNATURE DATE of the Agreement by all the Parties and shall remain effective for five (5) years, notwithstanding the expiry or early termination of the Agreement.

6.7 The provisions of this Article shall apply subject to the provisions of Article 5 hereof.

6.8 The provisions of Articles 5.6 and 6 may not prevent:

- either the obligation binding on all persons involved in the WORK SCHEDULE to present an activity report to the structure to which they report as such communication does not represent disclosure within the meaning of industrial property legislation,

- or the oral defence of final papers and theses by students whose scientific work relates to the purpose of the Agreement, as such defence is organised whenever necessary so as to ensure the confidentiality of the RESULTS, whilst complying with effective university regulations.

## **ARTICLE 7 – WARRANTIES**

7.1 The Relevant Parties of the GIS CBF undertake to deliver the PRODUCTS to the Beneficiary, via their laboratories, as soon as reasonably possible.

7.2 As the PRODUCTS are of an experimental nature, some of their features are unknown. They may possibly have dangerous properties and should therefore be used with all due care.

The PRODUCTS and the INFORMATION are sent "as is", without an express or tacit warranty, in respect of their commercial nature or their compatibility for a specific use, or their novelty, safety, purity, harmlessness, non-toxicity, activity, usefulness or compliance or as to whether they infringe the intellectual property rights of third Parties.

Under no circumstances may the Relevant Parties of the GIS CBF be held liable owing to the use and/or warehousing of these PRODUCTS and/or their extracts, reproductions or derivatives or the INFORMATION.

The Relevant Parties of the GIS CBF only warrant as to the material existence of the PRODUCTS and the INFORMATION.

7.3 The possible uncertainties and risks as regards performance of the Agreement, use of the Products, the INFORMATION, the RESULTS and their transport / transfer are the sole responsibility of the Beneficiary which accepts such.

7.4 The Beneficiary has sole responsibility for ensuring that the use of the PRODUCTS, the INFORMATION and the RESULTS comply with applicable legislation and regulations and, in particular, but non-exhaustively, regulations applying to handling, warehousing and use of biological or hazardous materials.

7.5 In the event of the supply of PRODUCTS or INFORMATION belonging to several Relevant Parties of the GIS CBF, the latter shall individually assume their noted liability in respect of the PRODUCTS and INFORMATION which they provide, within the limits set forth in the previous paragraphs. No joint and several liability whatsoever (legal, financial, etc.) may be invoked by the Beneficiary in the event of a dispute.

## **ARTICLE 8 – TERMINATION – EXPIRY**

8.1 The Agreement may be terminated by one of the Parties should another Party breach one or more of the obligations set forth herein. Such termination shall take effect two (2) months after the plaintiff Party sends a registered letter with acknowledgment of receipt setting-out the reasons for the complaint unless, within said timeframe, the defaulting Party were to have complied with its obligations or has provided proof that it is unable to do so owing to an event of force majeure. The exercising of this right of termination does not discharge the defaulting Party from complying with the obligations which it has committed itself to until the effective termination date, without prejudice to payment of the damages owed by the defaulting Party to compensate for the loss which may have been suffered by the plaintiff Party owing to the early termination of the Agreement.

8.2 Following termination for any reason whatsoever, or on the Agreement's expiry date, the Beneficiary undertakes, at the written request of the USCBF-CN or the Relevant Parties of the GIS CBF, and within the thirty (30) days following said request, to return to the Relevant Parties of the GIS CBF, or to destroy, the PRODUCTS, documents and other elements containing the INFORMATION which are in its possession.

8.3 Notwithstanding the expiry or termination of the Agreement for any reason whatsoever, the provisions of Articles 5 and 6 shall remain fully effective.

# ARTICLE 9- WAIVER

Should a Party fail to invoke a breach by another Party of one of its obligations hereunder, this shall not be construed as a waiver of compliance with the obligation in question in the future.

## **ARTICLE 10 – ENTIRETY AND LIMITS OF THE AGREEMENT**

10.1 The Agreement and its Appendices, which represent an integral part of the Agreement, express the entirety of the Parties' agreement concerning the purpose of the Agreement and take precedence over any and all prior written or oral agreement relating thereto. No general or specific condition set forth in any of the documents sent or provided to the Parties may be incorporated into the Agreement.

10.2 The Agreement may only be modified or extended by means of an amendment signed by the Parties' duly-authorised representatives.

10.3 It is understood that the relationships established between the Parties in respect of this Agreement do not grant any rights other than those mentioned herein.

In particular, it is expressly agreed that the Agreement does not grant the Beneficiary any right over any of the patents of the Relevant Parties of the GIS CBF, nor any right to use the PRODUCTS and the INFORMATION for any product or process for valuable consideration or commercial purposes.

Moreover, each Relevant Party of the GIS CBF shall remain entitled to work with third parties on the PRODUCTS or on scientific projects similar to the WORK SCHEDULE.

## **ARTICLE 11 - TRANSFER OF THE AGREEMENT**

The present Agreement cannot be given up to a third party without prior and written authorization of the Parties.

## **ARTICLE 12 - CONFIDENTIALITY OF THE AGREEMENT**

The signature, the existence and the execution of the present Agreement will be kept confidential by the Parties and will not be revealed by the one or the other one of them without the written agreement prerequisite of the other Party

## ARTICLE 13 – DISPUTES – GOVERNING LAW

13.1 The Agreement and its Appendices shall be subject to French legislation and regulations.

13.2 In the event of a problem concerning the validity, interpretation or performance of the Agreement, the Parties shall endeavour to settle their disagreement out-of-court.

13.3 In the event of a persistent disagreement, the dispute shall be referred to the French Courts having jurisdiction.

## ARTICLE 14 – NOTICES

Any notice required in respect of the Agreement shall be served by registered letter with acknowledgement of receipt sent to the Party in question at the following address:

For the USCBF-CN: UAR 3035 "*Unité support de ChemBioFrance et de la Chimiothèque Nationale*" ENSCM 8, rue de l'Ecole Normale 34296 Montpellier cedex 5

For the Beneficiary:

## Article 15 – INVALIDITY OF A CLAUSE

If one or more provisions of the Agreement were held to be invalid or declared as such under a treaty, act or regulation, or even following a final decision from a Court having jurisdiction, the other provisions shall keep all their effectiveness and scope. In this case, the Parties shall immediately make the required changes by respecting, insofar as possible, the consensus which existed when the Agreement was signed.

Drafted in xxx (x) originals,

# For the CNRS:

Name:

Function:

Date:

Signature:

# For the other Relevant Parties of the GIS CBF (repeat for each relevant partie):

Name:

Function:

Date:

Signature:

# For the Beneficiary

Name:

Funtion:

Date:

Signature:

## Appendix I List of molecules supplied by the USCBF-CN and of the Laboratories and Relevant Parties of the GIS CBF, the owners of said molecules.

\*\*\*

Appendix II WORK SCHEDULE.

\*\*\*

# Appendix III Details of costs.

In accordance with the financial conditions of access to the Chimiothèque Nationale below, please send us an order for the amount of :

## XXX € HT (XXX€ TTC) to :

CNRS - USCBF-CN 240 Av. du Professeur Emile Jeanbrau 34296 MONTPELLIER Cedex 5 Siret 180 089 013 00395 VAT FR40180089013

# Financial conditions for access to the National Chemical Library and procedure for transferring User contributions to GIS CBF Laboratories.

#### 1) Pricing

a. Postage and packing :

As of 01/01/2024, postage and packaging charges are set as follows:

1- products in solution prepared by Evotec: an estimate will be sent to you with the MTA. Depending on the service requested, the fee for plate preparation is set according to the CNRS auditable fee schedule for the Chimiothèque Nationale, in force since January 1, 2024: https://chembiofrance.cn.cnrs.fr/fr/static/dl/DEC246877DR13.pdf

2- CNE: the fee is set according to the CNRS auditable fee schedule for the Chimiothèque Nationale, in force since January 1, 2024.

3- Bulk products: €20 excl. tax/mg

These rates are subject to change by decision of the Steering Committee, with repayment based on the same principles as those set out in point 2 below. These rates will be posted on the ChemBioFrance website, so that potential users are aware of them.

- these faces will be posted of the enembior fallee website, so that potential users are aware
  - b. Right of access to PRODUCTS

c. OPTION - Lump-sum payment in full discharge of obligations

In the event of the PRODUCTS being developed by the Beneficiary alone, a lump-sum payment in full discharge of liabilities will be paid to the CNRS, which will redistribute it between the supervisory bodies of the laboratory(ies) concerned, in the amount of :

- 40,000 Euros (excluding VAT) plus management costs for the development of one (1) PRODUCT
- 60,000 Euros plus VAT and management fees for the development of two (2) PRODUCTS
- 75,000 Euros plus tax plus management fees for the development of three (3) PRODUCTS
- An additional amount of 15,000 Euros (excluding VAT) plus management fees for each additional molecule.

The Relevant Parties of the GIS CBF agree that a repayment agreement will be drawn up between the CNRS and the Beneficiary for this purpose.]

# 2) Payment of fees.

The CNRS Occitanie Est Delegation will be responsible for issuing invoices (prepared by the USCBF-CN) and making repayments to member laboratories of the sums due to them. Principle of distribution :

- on bulk and plate substances :

- Packaging and shipping costs: 4/5 paid to one of the laboratory's trustees, who will pay the other trustees their share, subject to current agreements.
- Case management fees: 1/5 paid to USCBF-CN.
- Lump-sum payment in full discharge :
  - Indemnity and management fees: paid to one of the laboratory's trustees, who will pay the other trustees their share, subject to applicable agreements.

For the essential chemical library (CNE), it has been agreed that all fees charged to users will be paid to USCBF-CN, to help finance joint actions.